Tune in NOW for Breast Cancer Breakthroughs! Learn how researchers are changing the game with new hormone therapies for ER-positive #breastcancer from Sean Fanning & Dr. Priya Rastogi. Click here to watch: bit.ly/3X1yPW0

Celebration of science and friendship at #PCFRetreat24 honoring the brilliant Felix Feng - a force, scientific legend, and visionary. Thank you Felix for always being such a supportive collaborator and kind scientific advisor! Prostate Cancer Foundation PCF Science

Humanized mice reveal role of immune system in #ProstateCancer therapy efficacy. Andrea Miyahira Prostate Cancer Foundation hosts Dr. Steven Kregel to discuss innovative humanized mouse models for studying metastatic #PCa 🧬🐭 Dr. Kregel explains how these models, using human stem cells, enable

#AACR #AACRLiqBiip24 #prostatecancer CTC

NIH funding generated $2.46 for every $1 funded in 2023. Important info for scientific advocacy in the years ahead- science is a quantifiable investment, not just a cost. H/t to Nicole C Rust, PhD for sharing! fiercebiotech.com/research/repor…

Russell Szmulewitz gives a great update on the clinical management of metastatic prostate cancer. #SBUR2024

Good to see my two mentors who got me started in the prostate world share the stage.

Modeling human prostate cancer is challenging. Humanized mouse models offer several advantages. Learn how these models can improve our understanding of immune system interactions. Andrea Miyahira & Steve Kregel, PhD discuss on UroToday.com: tinyurl.com/54jexk3x

Spotlight on Cancer Research Resources— Clinically Relevant Humanized #MouseModels of #MetastaticProstateCancer Facilitate Therapeutic Evaluation. doi.org/10.1158/1541-7… #openaccess

PUBLISHED! Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden #ProstateCancer Academy Meeting. #PCFAcademy Marina Sharifi Roni Haas Asmaa E. (She/her) Alok Tewari Lisa Chesner, PhD Laura Sena Howard Soule Andrea Miyahira onlinelibrary.wiley.com/doi/10.1002/pr…

Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer out on Cancer Discovery This study investigates how androgen-dependent #ProstateCancer evades immune detection by downregulating major histocompatibility complex class I

The two faces of FOXA1 muts in PCa. Congrats to Justin Hwang for this revised classification of FOXA1 alts in PCa. Different FOXA1 classes have different biologic behaviors, clinical outcomes & racial clustering, esp. Class 1B and 2. @UMNcancer Scott Dehm aacrjournals.org/clincancerres/…

Elevated CBP/p300 expression linked to poor outcomes in advanced #ProstateCancer. Ayesha Shafi, PhD Center for Prostate Disease Research joins Andrea Miyahira Prostate Cancer Foundation to discuss AR coactivators CBP/p300 in prostate cancer and research revealing that CBP/p300 expression increases as prostate cancer

In memory of Dr. Felix Feng. Thank you European Urology for honoring our beloved colleague and friend, gone too soon. We miss you Felix Mary Feng Nancy Lin, MD PCF Science sciencedirect.com/science/articl…

"Flawed assumptions could be spoiling cancer immunotherapy research." cen.acs.org/biological-che…

Proud to announce the publication of my master’s student Audris’s work on the pro-survival role of the linage specific, AR-cofactor NKX3.1 in prostate cancer cells! Take a look 👀 mdpi.com/2072-6694/17/2…

Andrea Apolo, M.D. As a prostate cancer survivor and patient advocate, this cannot possibly be what the American people would want if they understood the importance of NIH , research. I served on 8 panels for the CDMRP, the funding for research must continue.

ACT NOW! Tomorrow, Congress will vote on a CR that will result in a 57% cut to CDMRP budget and will impact the Research Programs that support urologic topics such as prostate cancer, kidney cancer, bladder cancer, kidney health, and more. CDMRP provides funding that accelerates

Now is not the time to halt #CancerResearch & prevention progress. We call on Congress to prioritize the fight against cancer by pivoting to a short-term CR to fund the gov’t while drafting full appropriations bills that include robust investment in cancer fightcancer.org/releases/acs-c…

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer biorxiv.org/content/10.110… #biorxiv_cancer